Supersymmetric Regularization, Two-Loop QCD Amplitudes and Coupling Shifts

We present a definition of the four-dimensional helicity (FDH) regularization scheme valid for two or more loops. This scheme was previously defined and utilized at one loop. It amounts to a variation on the standard 't Hooft-Veltman scheme and is designed to be compatible with the use of helicity states for "observed" particles. It is similar to dimensional reduction in that it maintains an equal number of bosonic and fermionic states, as required for preserving supersymmetry. Supersymmetry Ward identities relate different helicity amplitudes in supersymmetric theories. As a check that the FDH scheme preserves supersymmetry, at least through two loops, we explicitly verify a number of these identities for gluon-gluon scattering (gg to gg) in supersymmetric QCD. These results also cross-check recent non-trivial two-loop calculations in ordinary QCD. Finally, we compute the two-loop shift between the FDH coupling and the standard MS-bar coupling, alpha_s. The FDH shift is identical to the one for dimensional reduction. The two-loop coupling shifts are then used to obtain the three-loop QCD beta function in the FDH and dimensional reduction schemes.Comment: 44 pages, minor corrections and clarifications include

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and cardiovascular organ support-free days, on an ordinal scale combining in-hospital death (assigned a value of -1) and days free of organ support to day 21. The trial uses a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence, or futility. An odds ratio greater than 1 represented improved survival, more organ support-free days, or both. RESULTS: Both tocilizumab and sarilumab met the predefined criteria for efficacy. At that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control. The median number of organ support-free days was 10 (interquartile range, -1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sarilumab group, and 0 (interquartile range, -1 to 15) in the control group. The median adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control, yielding posterior probabilities of superiority to control of more than 99.9% and of 99.5%, respectively. An analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a hazard ratio for the comparison with the control group of 1.61 (95% credible interval, 1.25 to 2.08) and a posterior probability of superiority of more than 99.9%. All secondary analyses supported efficacy of these interleukin-6 receptor antagonists. CONCLUSIONS: In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.)